secwatch.observer — SEC 8-K summary
======================================

Issuer:     SeaStar Medical Holding Corp (ICU)
CIK:        0001831868
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001437749-25-034834
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SeaStar Medical Q3 revenue $0.2M, net loss $3.5M; QUELIMMUNE orders rising
--------------------------------------------------------------------------

- Net revenue $0.2M (Q3 2024: $0.1M); net loss $3.5M ($0.13/sh) vs $4.5M ($1.10/sh) a year ago.
- Cash $13.8M at Sep 30, 2025, up from $1.8M at Dec 31, 2024; raised $12.4M in Q3 via equity and warrant exercise.
- Three top children's hospitals adopted QUELIMMUNE; Q4 orders to date exceed full Q3 orders.
- NEUTRALIZE-AKI trial interim analysis showed positive safety/efficacy signal; enrollment target raised to 339 patients (146 enrolled).
- QUELIMMUNE SAVE registry shows 76% 60-day and 71% 90-day survival in 21 pediatric AKI patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/0001437749-25-034834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/icu20250829_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer